Halozyme (HALO) Loses 9% on Weak Earnings

We recently published 10 Losing Stocks in an Otherwise Optimistic Market. Halozyme Therapeutics Inc. (NASDAQ:HALO) was one of the worst performers on Wednesday.

Halozyme snapped a two-day winning streak on Wednesday, shedding 9.01 percent to finish at $73.23 as investors digested a weak earnings performance in both the fourth quarter and full-year 2025.

In an updated report, Halozyme Therapeutics Inc. (NASDAQ:HALO) said that net income last year fell by 28.6 percent to $317 million from $444 million in 2024, despite revenues surging by 37 percent to $1.396 billion from $1.01 billion year-on-year.

Tyler Olson/Shutterstock.com

Total revenues were said to be primarily driven by a 52 percent jump in royalties and strong sales from Enhanze partner products.

In the fourth quarter, Halozyme Therapeutics Inc. (NASDAQ:HALO) swung to a net loss of $141.59 million from a $137 million net income in the same period a year earlier, but total revenues increased by 51.6 percent to $451.77 million from $298 million year-on-year.

Looking ahead, Halozyme Therapeutics Inc. (NASDAQ:HALO) is targeting to generate between $1.71 billion and $1.81 billion in revenues this year, as well as  $2 billion in 2028.

Royalty revenues alone are projected at $1.13 billion to $1.17 billion, while adjusted EBITDA is expected to be at $1.125 billion to $1.205 billion. Non-GAAP diluted EPS is pegged at $7.75 to $8.25.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.